Completed PHASE3 INTERVENTIONAL NCT00034892

CAFE Comparison of Atypicals in First Episode of Psychosis

Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison

Sponsor: AstraZeneca

Conditions Mental Disorders Mental Health Psychotic Disorders Schizophrenia

Interventions Olanzapine, risperidone

Updated 6 times since 2017 Last updated: Jan 3, 2013 Started: Mar 31, 2002 Primary completion: Mar 31, 2005 Completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00034892, this PHASE3 trial focuses on Mental Disorders and Mental Health and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2002, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
University of North Carolina

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Augusta, United States , Boston, United States , Brooklyn, United States , Butner, United States , Calgary, Canada , Chapel Hill, United States , Charlotte, United States , Chicago, United States , Cincinnati, United States and 16 more locations